A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Inclusion Criteria:

• Diagnosis of previously untreated multiple myeloma (MM)

• Have a confirmed diagnosis and eligible for high dose chemotherapy and autologousstem cell transplantation, and an Eastern Cooperative Oncology Group (ECOG)performance status score of 0,1 or 2

Exclusion Criteria:

• previous treatment for Multiple Myeloma

• Primary amyloidosis, Plasma Cell Leukemia or Smoldering Multiple Myeloma

• Prior or concurrent exposure to systemic therapy or SCT (Stem Cell Transplantation)for any plasma cell dyscrasia, with the exception of an emergency use of a shortcourse (equivalent of dexamethasone 40 mg/day for a maximum 4 days) ofcorticosteroids before treatment, or received an investigational drug or used aninvasive investigational medical device within 4 weeks before Cycle 1, Day 1

• history of malignancy (other than Multiple Myeloma) within 10 years before the dateof randomization, except for the following if treated and not active: basal cell ornonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ,ductal carcinoma in situ of breast, or International Federation of Gynecology andObstetrics (FIGO) Stage 1 carcinoma of the cervix

• known chronic obstructive pulmonary disease (COPD) or moderate to severe asthma

• any concurrent medical or psychiatric condition or disease (eg, autoimmune disease,active systemic disease, myelodysplasia) that is likely to interfere with the studyprocedures or results, or that in the opinion of the investigator, would constitutea hazard for participating in this study